Medigene AG maintained guidance for the fiscal year 2023. The Management Board therefore maintains its guidance for fiscal year 2023 published in the annual report 2022 on March 29, 2023, in its entirety.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.44 EUR | 0.00% | -6.80% | -5.57% |
08/05 | Medigene Boosts Share Capital Via Rights Offering, Private Placement | MT |
02/05 | Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 - Targeted T Cell Receptor | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.57% | 38.09M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- MDG1 Stock
- News Medigene AG
- Medigene AG Maintains Guidance for the Fiscal Year 2023